178 related articles for article (PubMed ID: 6342789)
1. [Therapeutic effects of bezafibrate in hyperlipidemia].
Kunesová M; Honková M; Zeman M; Mares P; Skorepa J
Cas Lek Cesk; 1983 May; 122(20):628-31. PubMed ID: 6342789
[No Abstract] [Full Text] [Related]
2. [Carbohydrate metabolism in bezafibrate therapy. Controlled study of glibenclamide-treated diabetics with hyperlipidemia].
Janka HU; Standl A; Holler HD; Mehnert H
MMW Munch Med Wochenschr; 1982 May; 124(21):535-7. PubMed ID: 6810123
[No Abstract] [Full Text] [Related]
3. Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients.
Grützmacher P; Scheuermann E; Lang W
Proc Eur Dial Transplant Assoc; 1981; 18():169-75. PubMed ID: 7036147
[TBL] [Abstract][Full Text] [Related]
4. Clinical research into the hypolipemic and platelet antiaggregant activity of plafibride, Carried out in double-blind conditions and in comparison with clofibrate.
Palmieri B; Gasparini Casari M; DiBlasio P; Zirilli E
Arzneimittelforschung; 1981; 31(10a):1863-6. PubMed ID: 7032534
[TBL] [Abstract][Full Text] [Related]
5. [Effect of bezafibrate on lipid and apoprotein levels in patients with idiopathic hypertriglyceridemia].
Naruszewicz M; Nowicka G; Szostak WB; Kłosiewicz-Latoszek L
Kardiol Pol; 1982; 25(7-8):527-31. PubMed ID: 7169740
[No Abstract] [Full Text] [Related]
6. [Effect of bezafibrate on the carbohydrate metabolism of 17 diabetics with hyperlipidemia].
Stratmann FW; Holler HD; Hofmann H
Med Welt; 1981 Feb; 32(8):268-71. PubMed ID: 7207168
[No Abstract] [Full Text] [Related]
7. [Efficacy of bezafibrate and fenofibrate on elevated blood lipids in HLP type IIa, IIb and IV].
Schwartzkopff W; Luley C; Scheffler W; Lehmann-Leo W; Schilling A; Wegscheider K
Med Welt; 1982 Apr; 33(17):631-7. PubMed ID: 7098826
[No Abstract] [Full Text] [Related]
8. [Study of the antilipemic effect of etofibrate (Lipo-Merz)].
Słowińska R; Bochenek W; Unlot J
Pol Tyg Lek; 1983 Apr; 38(17):529-32. PubMed ID: 6356087
[No Abstract] [Full Text] [Related]
9. [A comparison of bezafibrate and clofibrate in type II B and type IV hyperlipoproteinemia].
Bolzano K; Krempler F; Schellenberg B; Schlierf G
Acta Med Austriaca; 1979; 6(3):90-4. PubMed ID: 547652
[TBL] [Abstract][Full Text] [Related]
10. [Lipid-lowering effect of etofibrate, bezafibrate and xanthinol nicotinate in patients with hyperlipoproteinemias].
Machalke K; Djaja S; Richter E
Ther Ggw; 1982 May; 121(5):301-11. PubMed ID: 6953613
[No Abstract] [Full Text] [Related]
11. [Double-blind study of the therapeutic activity of a new hypolipemic drug: etofibrate].
Altomonte L; Mingrone G; Negrini A; De Cunto F; Greco AV
Clin Ter; 1981 Jan; 96(1):31-8. PubMed ID: 7016409
[No Abstract] [Full Text] [Related]
12. [Bezafibrate and delayed action etofibrate in hyperlipidemia].
Lang PD; Vollmar J
Dtsch Med Wochenschr; 1983 Feb; 108(8):302-5. PubMed ID: 6825604
[No Abstract] [Full Text] [Related]
13. [Treatment of hyperlipoproteinaemia in diabetic patients (author's transl)].
Bruneder H; Klein HJ
Dtsch Med Wochenschr; 1981 Dec; 106(49):1653-6. PubMed ID: 7308007
[TBL] [Abstract][Full Text] [Related]
14. Bezafibrate does not influence the QT interval in man.
Olsson AG; Ekelund LG; Lang PD; Vollmar J
J Cardiovasc Pharmacol; 1983; 5(2):341-2. PubMed ID: 6188913
[No Abstract] [Full Text] [Related]
15. [Plafibride treatment of hyperlipidemias type II and IV].
Soler J; Vinzia C; Gómez JM; Morató J
Med Clin (Barc); 1984 May; 82(19):840-2. PubMed ID: 6738212
[No Abstract] [Full Text] [Related]
16. [Use of etofibrate in the treatment of patients with hyperlipidemia and arteriosclerosis obliterans of the legs].
Dembińska-Kieć A; Kostka-Trabka E; Grodzińska L; Bieroń K; Kedzior A; Basista M; Zmuda A; Trabka E; Sławiński M; Czarnecka B
Pol Tyg Lek; 1987 Dec 21-28; 42(51-52):1643-8. PubMed ID: 3330798
[No Abstract] [Full Text] [Related]
17. The antilipemic effectiveness of aluminium clofibrate on hyperlipidemic patients with or without diabetes mellitus.
Lam HC; Li SH; Wang JT; Tang KT; Ho LT
Zhonghua Yi Xue Za Zhi (Taipei); 1987 Nov; 40(5):463-70. PubMed ID: 3332236
[No Abstract] [Full Text] [Related]
18. [Pharmacology and mechanism of action of etofibrate].
Schatton W
Med Welt; 1982 Sep; 33(38):1310-4. PubMed ID: 6752630
[No Abstract] [Full Text] [Related]
19. [An alternative in the therapy of primary hyperlipemias: etofibrate in depot preparations].
Füsgen I; Summa JD
Med Klin; 1980 Nov; 75(23):823-5. PubMed ID: 7442597
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of the lipid-lowering agents clofibrate and bezafibrate in patients with hyperlipoproteinemias IIa and IIb].
Kokot F; Szczechowska E
Z Gesamte Inn Med; 1981 Jul; 36(13):454-7. PubMed ID: 7025475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
